CN1194156A - Life gate adaptagen - Google Patents

Life gate adaptagen Download PDF

Info

Publication number
CN1194156A
CN1194156A CN98101352A CN98101352A CN1194156A CN 1194156 A CN1194156 A CN 1194156A CN 98101352 A CN98101352 A CN 98101352A CN 98101352 A CN98101352 A CN 98101352A CN 1194156 A CN1194156 A CN 1194156A
Authority
CN
China
Prior art keywords
radix
adaptagen
melatonin
chinese medicine
life gate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98101352A
Other languages
Chinese (zh)
Inventor
赵治平
焦玉清
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HANDAN CITY ADAPTAGEN BIOLOGY INST
Original Assignee
HANDAN CITY ADAPTAGEN BIOLOGY INST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HANDAN CITY ADAPTAGEN BIOLOGY INST filed Critical HANDAN CITY ADAPTAGEN BIOLOGY INST
Priority to CN98101352A priority Critical patent/CN1194156A/en
Publication of CN1194156A publication Critical patent/CN1194156A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Life gate adaptagen, one Chinese medicine composite for curing cancer and cardio- and cerebral- angiopathy, consists of schisandra 25-35%, later silkworm excrement 10-15%, Spica Prunellae 5-10%, Rhizoma Corydalis Decumbentis 5-12%, rhodiola root 5-10%, Radix Acanthopanacis Senticosi 3-8%, Radix Bupleuri 2-5%, hexabutylsaccharide 8-12% and melatonin 1-2.5%. The present invention has deternined cure effect, can regulate body's function and strengthen immunity while cure disease. It has effective rate of 90%.

Description

Life gate adaptagen
The present invention relates to a kind of Chinese medicine composition for the treatment of cancer and cardiovascular and cerebrovascular disease.
At present the treatment for cancer method has two big classes, and a class is a traditional remedies, and as operation, radiotherapy, chemotherapy, these class methods are only paid attention to " eliminating evil ", and have ignored integral body, and is strong to the tissue of tumor and cell removing and lethality, but damaging quite big to body.In addition tumour patient mostly in finding to be all, late period, the whole body resistance reduces, thus not too suitable to traditional method, also can quicken to worsen, promote death sometimes.Another kind of is Chinese medicine, and this class methods relative adaptation disease is wide, also very pays attention to integral body, but because the shortage Systems Theory instructs, does not have the property of commander medicine, so general effect is relatively poor.
The purpose of this invention is to provide a kind of determined curative effect, can treat to be beneficial to again simultaneously and regulate the whole treatment cancer and the Chinese medicine composition-life gate adaptagen of cardiovascular and cerebrovascular disease.
The object of the present invention is achieved like this: a kind of Chinese medicine composition that is used for the treatment of cancer and cardiovascular and cerebrovascular disease--life gate adaptagen, it is characterized in that forming: Radix Schisandrae Bicoloris 25--35% by following component and part by weight, late Bombyx mori L. 10--15%, Spica Prunellae 5--10%, Rhizoma Corydalis Decumbentis 5--12%, Radix Rhodiolae 5--10%, Radix Et Caulis Acanthopanacis Senticosi 3--8%, Radix Bupleuri 2--5%, chitosan 8--12%, melatonin 1--2.5%.
Purpose of the present invention can also following manner realize: the part by weight of each component is: Radix Schisandrae Bicoloris 33%, late Bombyx mori L. 13%, Spica Prunellae 10%, Rhizoma Corydalis Decumbentis 10%, Radix Rhodiolae 10%, Radix Et Caulis Acanthopanacis Senticosi 6%, Radix Bupleuri 3%, chitosan 10%, melatonin 2.5%.
The present invention has following advantage and good effect: determined curative effect, and not only be used for the treatment of but also can adjust the whole body function simultaneously, enhance immunity, through clinical anticancer patient 30 example statistics, total effective rate is 90%.Its mechanism of action is, Radix Schisandrae Bicoloris, Radix Rhodiolae, Radix Et Caulis Acanthopanacis Senticosi, chitosan belong to adaptogen class material together, the collaborative merit of tool not only between four, and four component accounts for 2/3rds of total component, guaranteed that our adaptogen occupies an leading position, its major function is an enhance immunity, conditioning whole body, antitonic, radioprotective, antibiotic, anticancer, antitoxin, fatigue-resisting function; Health is had concurrently protective effect and stimulates the function of repairing, thereby can help each physiological function of health to reach optimum state.Evening, Bombyx mori L. had a surname to lead turbid merit clearly; The little suffering of Spica Prunellae and sweet among the eliminating stagnation, has the merit with positive yin nourishing concurrently; Summer incompetent qi and blood circulation promotion, the meridian dredging, the pain that relieves the pain, the three share, and can not only proofread and correct the property of the astringent therapy of Radix Schisandrae Bicoloris, and exchanges that to reach state of internal organs mechanism of qi also essential.Radix Bupleuri, but few with sending up the lucid YANG, because of falling of vigour, must this in liter, though so survival dose is few, but compatibility key.Melatonin is a pinus secretions, the significant anti-aging effects of tool, and every day, 2mg can obviously improve sleep, and this is the important substance basis that adapts to the integrally-regulated effect of originality.
Elaborate below in conjunction with embodiment:
One, proportioning components: in per 15 No. 2 capsule finished product net content 3g, wherein each component content is: Radix Schisandrae Bicoloris 1g, late Bombyx mori L. 0.4g, Spica Prunellae 0.3g, Rhizoma Corydalis Decumbentis 0.3g, Radix Rhodiolae 0.3g, Radix Et Caulis Acanthopanacis Senticosi 0.2g, Radix Bupleuri 0.1g, chitosan (deacetylation is more than 85%) 0.325g, melatonin 0.075g.
Two, preparation method: other Chinese herbal medicine except that chitosan, melatonin are mixed, pulverize, cross 100 mesh sieves, add chitosan again, melatonin fine powder, the capsule of packing into No. 2 after fully mixing, every net content 200mg.
Three, indication: be applicable to cancer, particularly in, terminal cancer and cardiovascular and cerebrovascular disease.Also can be used for hepatopathy, diabetes, retinopathy and health of older persons.
Four, usage and dosage: oral, three times on the one, each 1g.
Five, clinical anticancer statistical effect: use the present invention and treat late tumor 30 examples, wherein: esophageal carcinoma 5 examples, gastric cancer 5 examples, pulmonary carcinoma 8 examples, hepatocarcinoma 4 examples, adnexal carcinoma 2 examples, mammary cancer 1 example, osteocarcinoma 1 example, other 4 example.All have the 1--3 place to shift before all patient, 80% patient carried out 1--2 kind traditional method and failed to respond to any medical treatment, and had the above Chinese medicine of 1 class and other method to fail to respond to any medical treatment.Through using life gate adaptagen treatment three above statistical result of week of the present invention as follows: clinical cure 4 examples, 8 examples that are clearly better, effective 15 examples, invalid 3 examples, total effective rate 90%.The shortest person of doing well,improving seven days is generally more than 20 days.Tumor auxiliary examination (X-ray, B ultrasonic, CT, MRI) can check out that the person of dwindling is greatly about more than 1 month; Disappear or disappear generally three of medications more than the first quarter moon substantially.Through clinical practice, the present invention also has significant curative effect for the treatment cardiovascular and cerebrovascular disease in addition.

Claims (2)

1, a kind of Chinese medicine composition that is used for the treatment of cancer and cardiovascular and cerebrovascular disease--life gate adaptagen, it is characterized in that forming: Radix Schisandrae Bicoloris 25--35% by following component and part by weight, late Bombyx mori L. 10--15%, Spica Prunellae 5--10%, Rhizoma Corydalis Decumbentis 5--12%, Radix Rhodiolae 5--10%, Radix Et Caulis Acanthopanacis Senticosi 3--8%, Radix Bupleuri 2--5%, chitosan 8--12%, melatonin 1--2.5%.
2, Chinese medicine composition--the life gate adaptagen of treatment cancer according to claim 1 and cardiovascular and cerebrovascular disease, the part by weight that it is characterized in that each component is: Radix Schisandrae Bicoloris 33%, late Bombyx mori L. 13%, Spica Prunellae 10%, Rhizoma Corydalis Decumbentis 10%, Radix Rhodiolae 10%, Radix Et Caulis Acanthopanacis Senticosi 6%, Radix Bupleuri 3%, chitosan 10%, melatonin 2.5%.
CN98101352A 1998-04-10 1998-04-10 Life gate adaptagen Pending CN1194156A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN98101352A CN1194156A (en) 1998-04-10 1998-04-10 Life gate adaptagen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN98101352A CN1194156A (en) 1998-04-10 1998-04-10 Life gate adaptagen

Publications (1)

Publication Number Publication Date
CN1194156A true CN1194156A (en) 1998-09-30

Family

ID=5216638

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98101352A Pending CN1194156A (en) 1998-04-10 1998-04-10 Life gate adaptagen

Country Status (1)

Country Link
CN (1) CN1194156A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117566A3 (en) * 2005-05-03 2007-06-14 Ultra Biotech Ltd Botanical anticancer formulations
CN104173585A (en) * 2014-08-29 2014-12-03 北京世纪合辉医药科技股份有限公司 Adaptogen preparation containing rhodiola rosea and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117566A3 (en) * 2005-05-03 2007-06-14 Ultra Biotech Ltd Botanical anticancer formulations
CN104173585A (en) * 2014-08-29 2014-12-03 北京世纪合辉医药科技股份有限公司 Adaptogen preparation containing rhodiola rosea and preparation method thereof

Similar Documents

Publication Publication Date Title
CN1679864A (en) Chinese medicine preparation for treating bronchitis
CN101485834B (en) Chinese medicine for treating diabetes
CN115463200B (en) Traditional Chinese medicine composition and patch for treating adenoid hypertrophy and preparation method thereof
CN106963921A (en) It is a kind of to treat external medicine composition of the proliferation of mammary gland and preparation method thereof
CN101829248B (en) Traditional Chinese medicine for treating goiter
CN1194156A (en) Life gate adaptagen
CN1178679C (en) Medicine for treating asthma, acute and chronic bronchitis and emphysema
CN101979035A (en) Medicament for treating gynecological abnormal leucorrhea
CN102228624A (en) Medicament for treating pharyngitis and preparation method thereof
CN101837111A (en) Medicament for curing proliferation of mammary glands and preparation method thereof
CN1056517C (en) Anal fistula eliminating medicine
CN102293992B (en) Traditional Chinese medicine for treating radiation pneumonitis
CN1174769C (en) Chinese-medicinal bag tea for treating chronic pharyngitis and vocal fold disease and its preparing process
CN110496181B (en) Chinese medicinal capsule and its preparation method
CN101618102B (en) Chinese traditional medicine preparation for treating breast diseases and preparing method thereof
CN1263493C (en) Medicine for treating chronic bronchitis and asthma
CN107617039B (en) Traditional Chinese medicine composition for treating lumbar vertebrae hyperosteogeny and preparation thereof
CN105106468A (en) Antineoplastic traditional Chinese medicine composition for medical oncology
CN1145494C (en) Ebikang medicine for treating nasal disorders and its preparation method
CN104288623B (en) A kind of medicinal liquor for treating waist dish outstanding
CN103156938B (en) Hmong drug for treating diabetes mellitus
CN110742938A (en) Cough relieving tea and preparation method thereof
CN1068523C (en) Medicine for treating cancer and its preparing technology
CN110664931A (en) Traditional Chinese medicine for treating cough and preparation method thereof
CN110934949A (en) Traditional Chinese medicine for treating hydrocephalus and hematoma after cerebral hemorrhage and preparation method thereof

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication